Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Exelixis Inc. (EXEL)

NASDAQ: EXEL · Biological Products, (No Diagnostic Substances) · Alameda, CA

Our rating: Neutral

Call changed from Positive to Neutral at $69.39, moderate conviction, October 30, 2026.

Breaks if: The call turns Positive if revenue growth re-accelerates to 12% or above for two consecutive reported quarters, signaling franchise expansion that genuinely earns the premium multiple. It turns Cautious if net margin falls below 25% for two straight quarters — indicating the cost or competitive picture has shifted — or if annual revenue growth drops below 3%, compressing earnings against an unchanged elevated multiple. Neither condition is true at today's reported figures.

Key figures

Market value$15.8B
Revenue, last 12 months$2.5B
Net income, last 12 months$885M
Free cash flow, last 12 months$1.2B
Price to earnings17.8×
Free cash flow yield7.4%
Dividend yield0.0%
Operating margin40.2%
Return on equity44.3%
Beta to the S&P 5000.54
Volatility, annualized38.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
October 2, 2026$659M10.2%$0.85$277M
July 3, 2026$629M10.6%$0.82$301M
April 3, 2026$611M10.0%$0.79$250M
January 2, 2026$599M5.6%$0.88$332M
October 3, 2025$598M10.8%$0.69$289M
July 4, 2025$568M−10.8%$0.65$46M
April 4, 2025$555M30.6%$0.55$208M
January 3, 2025$567M18.2%$0.48$236M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

10 ledger entries and 26 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.